|Dr. J. Mel Sorensen||CEO, Pres & Director||571.33k||N/A||1957|
|Dr. Robert A. Beardsley||Co-Founder & COO||456.03k||N/A||1961|
|Mr. Christopher Degnan||CFO & Sec.||169.74k||N/A||1980|
|Mr. Joel F. Sussman||Chief Accounting Officer & Treasurer||N/A||N/A||1949|
|Dr. Dennis P. Riley Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Dr. Jon T. Holmlund||Chief Medical Officer||N/A||N/A||1957|
|Mr. Arthur J. Fratamico||Chief Bus. Officer||N/A||N/A||1966|
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer (HNC); and in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; in phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy; and has completed pilot placebo-controlled Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) for patients with locally advanced pancreatic cancer, as well as in Phase II clinical trial for hospitalized patients with COVID-19 disease. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with SBRT in patients with non-small cell lung cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Galera Therapeutics, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 8. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 8.